Clinical trials
EGFR clinical trials
Below are recruiting egfr clinical trials, each written for real people, not researchers. We’re tracking 239 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07181499RecruitingPhase 2
Chemotherapy with befotertinib for resistance to targeted lung cancer drugs
This trial tests a combination of chemotherapy and a targeted drug (befotertinib) for people with non-small cell lung cancer whose cancer has stopped responding to a common type of targeted therapy. It aims to see if this new sequence can help overcome resistance.
Guangzhou, GuangdongAges 18 years+ - NCT07100080RecruitingPhase 2/Phase 3
New drug vs chemotherapy for EGFR-mutated lung cancer
This trial tests a new drug called izalontamab brengitecan (BMS-986507) against standard chemotherapy (platinum plus pemetrexed) for people with a specific type of lung cancer that has an EGFR mutation and has stopped responding to newer targeted pills.
Irvine, CaliforniaAges 18 years+ - NCT07089641RecruitingPhase 1
Study of ERAS-801 for recurrent or newly diagnosed glioblastoma with EGFR changes
This trial tests an experimental drug called ERAS-801 for people with a type of brain cancer called glioblastoma or gliosarcoma that has a specific genetic change (EGFR amplification or mutation). The study has two groups: one for people whose tumor has come back after treatment, and another for older adults (70+) who are newly diagnosed. The drug targets the EGFR pathway, which may help slow tumor growth.
Los Angeles, CaliforniaAges 18 years+ - NCT05394831RecruitingPhase 1/Phase 2
Study of an EGFR-targeted drug for advanced lung cancer
This trial tests a new drug (JIN-A02) in people with advanced or metastatic non-small cell lung cancer (NSCLC) whose cancer has specific EGFR mutations. It mainly checks whether the treatment is safe and tolerable, and how the body handles the drug, with possible benefit depending on your mutation type.
Orange, CaliforniaAges 18 years+ - NCT07079475RecruitingPhase 1/Phase 2
Study of two targeted pills for EGFR-mutated lung cancer
This trial tests a new combination of two oral targeted drugs for people with advanced non-small cell lung cancer that has an EGFR mutation. It may help if you have already been treated with a third-generation EGFR pill or if you are starting treatment for the first time.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06343064RecruitingPhase 1/Phase 2
Vebreltinib plus PLB1004 for EGFR-mutant lung cancer with MET changes
This trial tests a combination of two targeted drugs (Vebreltinib and PLB1004) for people with advanced non-small cell lung cancer that has a specific EGFR mutation and has developed MET amplification or overexpression after previous EGFR-targeted therapy. The goal is to see if this combination can help shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06992739RecruitingPhase 2
Trilaciclib with chemotherapy for EGFR-mutant advanced lung cancer
This study tests whether adding trilaciclib to a new chemotherapy (sacituzumab tirumotecan) can help people with EGFR-mutant lung cancer that keeps growing after certain targeted treatments. The goal is to see if it slows the cancer and reduces side effects.
Xiamen, FujianAges 18–75 - NCT06975410RecruitingPhase 1/Phase 2
Trial of YH32364 for EGFR-positive solid tumors
This trial tests a new drug, YH32364, for people with advanced solid tumors that have high levels of EGFR protein. It looks at whether the drug can help when standard treatments have stopped working.
SeoulAges 18 years+ - NCT06960395RecruitingPhase 1
Study of VIR-5525 alone or with pembrolizumab for advanced solid tumors
This trial tests a new drug called VIR-5525, either alone or combined with pembrolizumab (an immunotherapy), for people with advanced solid tumors that have not responded to other treatments or cannot undergo standard therapy. It focuses on certain cancer types and tumors with a specific genetic change (EGFR amplification).
Scottsdale, ArizonaAges 18 years+ - NCT06418412Recruiting
Pan-Asian study for EGFR exon 20 insertion lung cancer
This trial is building a large database of lung cancer patients from Asia who have a specific EGFR mutation (exon 20 insertion). Your medical records and treatment information will be collected to help doctors learn more about this type of cancer and improve care.
SingaporeAges 21–99 - NCT06927986RecruitingPhase 3
Testing SYS6010 vs chemo for advanced EGFR-mutated lung cancer
This trial tests a new drug called SYS6010 compared to standard chemotherapy for people with EGFR-mutated lung cancer that has stopped responding to pill treatments. It may offer a new option if your current EGFR TKI is no longer working.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06905197RecruitingPhase 1
Study of DZD6008 for advanced NSCLC with EGFR mutations
This trial tests an oral drug called DZD6008 for people with advanced non-small cell lung cancer (NSCLC) that has certain EGFR mutations. It may be an option for those who have tried other EGFR treatments or are new to treatment.
New York, New YorkAges 18 years+ - NCT06813365RecruitingPhase 1
A targeted therapy for EGFR-mutated advanced lung cancer
This trial is testing a new targeted pill for people with EGFR-positive non-small cell lung cancer. It's designed for those whose cancer has grown after other treatments, and it works by blocking a specific protein that helps the cancer grow.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06802835RecruitingPhase 1/Phase 2
EGFR antibody plus immunotherapy and chemo for advanced nasopharyngeal cancer
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
Guangzhou, GuangdongAges 18–75 - NCT06784791RecruitingPhase 2
Amivantamab before surgery for EGFR-mutant lung cancer
This trial tests a new drug, amivantamab, given before surgery for people with a specific EGFR-mutated lung cancer. It aims to shrink tumors and improve surgical outcomes, and may be combined with standard chemotherapy in some patients.
HasseltAges 18 years+ - NCT06062823RecruitingPhase 2
Newer EGFR pill for advanced lung cancer with specific mutations
This trial tests a newer type of EGFR targeted therapy pill for people with advanced non-small cell lung cancer who have not had prior treatment and whose cancer has a specific genetic change called a PACC mutation. The goal is to see if the drug works well for this group.
SingaporeAges 21–99 - NCT06730477Enrolling by invitation
How well do targeted drugs work for EGFR lung cancer?
This trial studies whether changes in tiny particles in your blood (called exosomes) can show how well targeted therapy is working for lung cancer with an EGFR mutation. You may be eligible if you have this type of lung cancer and are starting your first treatment with a targeted drug.
Wuhan, HubeiAges 18–80 - NCT06716580Recruiting
Lung cancer screening for Asian and Latinx communities
This study uses a blood test to look for signs of lung cancer in people who have never smoked or smoked very little. It focuses on Asian and Latinx communities because certain gene changes are more common in these groups.
Boston, MassachusettsAges 40–80 - NCT06652048RecruitingPhase 2
High-dose Furmonertinib for advanced lung cancer after progression
This trial tests a higher dose of the targeted therapy Furmonertinib, either alone or with chemotherapy, for people with advanced non-small cell lung cancer that has progressed after initial treatment with a third-generation EGFR inhibitor like Osimertinib or Almonertinib.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05037331Recruiting
Osimertinib for advanced EGFR-mutated lung cancer
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
SingaporeAges 21–99 - NCT06247826Recruiting
Why amivantamab stops working in certain lung cancers
This study looks at how and why lung cancers with a specific EGFR mutation (exon 20 insertion) become resistant to the drug amivantamab. It collects blood and tumor samples from patients whose cancer has progressed on amivantamab to better understand resistance.
BordeauxAges 18 years+ - NCT05948813RecruitingPhase 2
TY-9591 for EGFR-mutant lung cancer spread to the brain
This phase 2 trial studies TY-9591 in people with advanced non-small cell lung cancer (NSCLC) that has spread to the brain and has specific EGFR mutations. It aims to see whether the medicine can control the cancer in the brain and the rest of the body, without needing immediate brain radiation.
Beijing, Beijing MunicipalityAges 18–80 - NCT05967689RecruitingPhase 2
Zipalertinib for lung cancer with EGFR exon 20 mutations
This Phase 2 trial tests zipalertinib (a targeted pill) in people with advanced non-small cell lung cancer (NSCLC) that has specific EGFR mutations, especially “exon 20 insertions.” It may help shrink tumors or slow cancer growth, including in some people with brain metastases.
Birmingham, AlabamaAges 18 years+ - NCT05559645Recruiting
Targeted oral pill for EGFR-mutated advanced lung cancer
This study tests an oral pill (DZD9008) that targets a specific genetic change in lung cancer called EGFR. If you have this mutation, the drug may shrink your tumor or slow its growth, especially if other treatments have stopped working or caused side effects.
Beijing, Beijing MunicipalityAges 18 years+
Hear when a new EGFR trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for egfr?
- Yes. Clin2 currently lists 239 recruiting egfr studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a egfr trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a egfr trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.